SEARCH:   Advanced

Blood, 15 August 2004, Vol. 104, No. 4, pp. 1094-1099. Prepublished online as a Blood First Edition Paper on April 20, 2004; DOI 10.1182/blood-2003-12-4266. This Article Full Text Full Text (PDF) All Versions of this Article: 2003-12-4266v1 104/4/1094    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Dietz, A. B. Articles by Vuk-Pavlovic, S. Search for Related Content PubMed PubMed Citation Articles by Dietz, A. B. Articles by Vuk-Pavlovic, S. Related Collections Immunobiology Phagocytes Apoptosis Oncogenes and Tumor Suppressors Signal Transduction Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  IMMUNOBIOLOGY Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo Allan B. Dietz, Lina Souan, Gaylord J. Knutson, Peggy A. Bulur, Mark R. Litzow, and Stanimir Vuk-Pavlovi From the Stem Cell Laboratory, Mayo Clinic Cancer Center, Rochester, MN; Division of Hematology, Department of Internal Medicine; Division of Transfusion Medicine, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN; and Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Rochester, MN. Imatinib mesylate (STI571, imatinib) inhibited DNA synthesis in primary human T cells stimulated with allogeneic mature dendritic cells or phytohemagglutinin (PHA) but did not induce apoptosis. The values for the concentration that inhibits 50% (IC50) of T-cell proliferation stimulated by dendritic cells and PHA were 3.9 µM and 2.9 µM, respectively, that is, within the concentration range found in patients treated with imatinib mesylate. Interestingly, imatinib mesylate did not inhibit expression of T-cell activation markers CD25 and CD69, although it reduced the levels of activated nuclear factor-B (NF-B) and changed phosphorylation or protein levels of Lck, ERK1/2, retinoblastoma protein, and cyclin D3. When T cells were washed free of imatinib mesylate, they proliferated in response to PHA, demonstrating that inhibition is reversible. Treatment with imatinib mesylate led to accumulation of the cells in G0/G1 phase of the cell cycle. The in vitro observations were confirmed in vivo in a murine model of delayed-type hypersensitivity (DTH). In mice treated with imatinib mesylate, DTH was reduced in comparison to sham-injected controls. However, the number of splenic T cells was not reduced showing that, similarly to in vitro observations, imatinib mesylate inhibited T-cell response, but did not cause apoptosis. These findings indicate that long-term administration of high-dose imatinib mesylate might affect immunity. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Imatinib mesylate: a novel immune suppressive agent? Richard T. Maziarz Blood 2004 104: 914-915. [Full Text] [PDF] This article has been cited by other articles: Y. NAGASAKI, T. MIYAMOTO, H. HENZAN, K. NAGAFUJI, M. HARADA, and K. AKASHI Longstanding Remission of Adult Onset Still's Disease Under Imatinib Therapy in a Patient with Chronic Myelogenous Leukemia J Rheumatol, June 1, 2009; 36(6): 1349 - 1350. [Full Text] [PDF] J. M. A. Daniels, A. Vonk-Noordegraaf, J. J. W. M. Janssen, P. E. Postmus, and R. van Altena Tuberculosis complicating imatinib treatment for chronic myeloid leukaemia Eur. Respir. J., March 1, 2009; 33(3): 670 - 672. [Abstract] [Full Text] [PDF] L. Senn, T. Kovacsovics, P. E. Tarr, and P. Meylan Peritoneal Tuberculosis After Imatinib Therapy Arch Intern Med, February 9, 2009; 169(3): 312 - 313. [Full Text] [PDF] C. Louvet, G. L. Szot, J. Lang, M. R. Lee, N. Martinier, G. Bollag, S. Zhu, A. Weiss, and J. A. Bluestone Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice PNAS, December 2, 2008; 105(48): 18895 - 18900. [Abstract] [Full Text] [PDF] H.-J. Kolb Graft-versus-leukemia effects of transplantation and donor lymphocytes Blood, December 1, 2008; 112(12): 4371 - 4383. [Abstract] [Full Text] [PDF] N. Larmonier, N. Janikashvili, C. J. LaCasse, C. B. Larmonier, J. Cantrell, E. Situ, T. Lundeen, B. Bonnotte, and E. Katsanis Imatinib Mesylate Inhibits CD4+CD25+ Regulatory T Cell Activity and Enhances Active Immunotherapy against BCR-ABL- Tumors J. Immunol., November 15, 2008; 181(10): 6955 - 6963. [Abstract] [Full Text] [PDF] S. J. Lee, M. Kukreja, T. Wang, S. A. Giralt, J. Szer, M. Arora, A. E. Woolfrey, F. Cervantes, R. E. Champlin, R. P. Gale, et al. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia Blood, October 15, 2008; 112(8): 3500 - 3507. [Abstract] [Full Text] [PDF] M. Cristofanilli, P. Morandi, S. Krishnamurthy, J. M. Reuben, B.-N. Lee, D. Francis, D. J. Booser, M. C. Green, B. K. Arun, L. Pusztai, et al. Imatinib mesylate (Gleevec(R)) in advanced breast cancer-expressing C-Kit or PDGFR-{beta}: clinical activity and biological correlations Ann. Onc., October 1, 2008; 19(10): 1713 - 1719. [Abstract] [Full Text] [PDF] R. Santachiara, R. Maffei, S. Martinelli, A. Arcari, F. Piacentini, E. Trabacchi, P. Alfieri, A. Ferrari, G. Leonardi, G. Luppi, et al. Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor Haematologica, August 1, 2008; 93(8): 1252 - 1255. [Abstract] [Full Text] [PDF] Y. Huang, E. O. Comiskey, R. S. Dupree, S. Li, A. J. Koleske, and J. K. Burkhardt The c-Abl tyrosine kinase regulates actin remodeling at the immune synapse Blood, July 1, 2008; 112(1): 111 - 119. [Abstract] [Full Text] [PDF] R. Weichsel, C. Dix, L. Wooldridge, M. Clement, A. Fenton-May, A. K. Sewell, J. Zezula, E. Greiner, E. Gostick, D. A. Price, et al. Profound Inhibition of Antigen-Specific T-Cell Effector Functions by Dasatinib Clin. Cancer Res., April 15, 2008; 14(8): 2484 - 2491. [Abstract] [Full Text] [PDF] A. E. Schade, G. L. Schieven, R. Townsend, A. M. Jankowska, V. Susulic, R. Zhang, H. Szpurka, and J. P. Maciejewski Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation Blood, February 1, 2008; 111(3): 1366 - 1377. [Abstract] [Full Text] [PDF] J. J. Gu, N. Zhang, Y.-W. He, A. J. Koleske, and A. M. Pendergast Defective T Cell Development and Function in the Absence of Abelson Kinases J. Immunol., December 1, 2007; 179(11): 7334 - 7343. [Abstract] [Full Text] [PDF] J. Chen, X. Zhang, and A. Fernandez Molecular basis for specificity in the druggable kinome: sequence-based analysis Bioinformatics, March 1, 2007; 23(5): 563 - 572. [Abstract] [Full Text] [PDF] P. Sinai, R. E. Berg, J. M. Haynie, M. J. Egorin, R. L. Ilaria Jr, and J. Forman Imatinib Mesylate Inhibits Antigen-Specific Memory CD8 T Cell Responses In Vivo J. Immunol., February 15, 2007; 178(4): 2028 - 2037. [Abstract] [Full Text] [PDF] S. Mumprecht, M. Matter, V. Pavelic, and A. F. Ochsenbein Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections Blood, November 15, 2006; 108(10): 3406 - 3413. [Abstract] [Full Text] [PDF] K. Shimizu, M. Hidaka, N. Kadowaki, N. Makita, N. Konishi, K. Fujimoto, T. Uchiyama, F. Kawano, M. Taniguchi, and S.-i. Fujii Evaluation of the Function of Human Invariant NKT Cells from Cancer Patients Using {alpha}-Galactosylceramide-Loaded Murine Dendritic Cells. J. Immunol., September 1, 2006; 177(5): 3484 - 3492. [Abstract] [Full Text] [PDF] K. M. Irvine, C. J. Burns, A. F. Wilks, S. Su, D. A. Hume, and M. J. Sweet A CSF-1 receptor kinase inhibitor targets effector functions and inhibits pro-inflammatory cytokine production from murine macrophage populations FASEB J, September 1, 2006; 20(11): 1921 - 1923. [Abstract] [Full Text] [PDF] N. Boissel, D. Rea, V. Tieng, N. Dulphy, M. Brun, J.-M. Cayuela, P. Rousselot, R. Tamouza, P. Le Bouteiller, F.-X. Mahon, et al. BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia. J. Immunol., April 15, 2006; 176(8): 5108 - 5116. [Abstract] [Full Text] [PDF] N. Boissel, P. Rousselot, E. Raffoux, J.-M. Cayuela, J. Soulier, N. Mooney, D. Charron, H. Dombret, A. Toubert, and D. Rea Imatinib mesylate minimally affects bcr-abl+ and normal monocyte-derived dendritic cells but strongly inhibits T cell expansion despite reciprocal dendritic cell-T cell activation J. Leukoc. Biol., April 1, 2006; 79(4): 747 - 756. [Abstract] [Full Text] [PDF] M. J. Mauro and R. T. Maziarz Stem Cell Transplantation in Patients With Chronic Myelogenous Leukemia: When Should It Be Used? Mayo Clin. Proc., March 1, 2006; 81(3): 404 - 416. [Abstract] [Full Text] [PDF] A. M. Wolf, D. Wolf, H. Rumpold, S. Ludwiczek, B. Enrich, G. Gastl, G. Weiss, and H. Tilg The kinase inhibitor imatinib mesylate inhibits TNF-{alpha} production in vitro and prevents TNF-dependent acute hepatic inflammation PNAS, September 20, 2005; 102(38): 13622 - 13627. [Abstract] [Full Text] [PDF] Z. Li, Y. Qiao, B. Liu, E. J. Laska, P. Chakravarthi, J. M. Kulko, R. D. Bona, M. Fang, U. Hegde, V. Moyo, et al. Combination of Imatinib Mesylate with Autologous Leukocyte-Derived Heat Shock Protein and Chronic Myelogenous Leukemia Clin. Cancer Res., June 15, 2005; 11(12): 4460 - 4468. [Abstract] [Full Text] [PDF] R. Seggewiss, K. Lore, E. Greiner, M. K. Magnusson, D. A. Price, D. C. Douek, C. E. Dunbar, and A. Wiestner Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner Blood, March 15, 2005; 105(6): 2473 - 2479. [Abstract] [Full Text] [PDF] S. Appel, A. Rupf, M. M. Weck, O. Schoor, T. H. Brummendorf, T. Weinschenk, F. Grunebach, and P. Brossart Effects of Imatinib on Monocyte-Derived Dendritic Cells Are Mediated by Inhibition of Nuclear Factor-{kappa}B and Akt Signaling Pathways Clin. Cancer Res., March 1, 2005; 11(5): 1928 - 1940. [Abstract] [Full Text] [PDF] H. Wang, F. Cheng, A. Cuenca, P. Horna, Z. Zheng, K. Bhalla, and E. M. Sotomayor Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance Blood, February 1, 2005; 105(3): 1135 - 1143. [Abstract] [Full Text] [PDF] A. Dietz, W. B. Johnson, G. J. Knutson, P. A. Bulur, B. Schulenberg, J. M. Beechem, F. G. Prendergast, and S. Vuk-Pavlovic Imatinib Mesylate Disrupts Cell Cycle Progression, Modifies the Nucleoskeleton and Suppresses Activation-Induced Transcription in Human T Cells. Blood (ASH Annual Meeting Abstracts), November 16, 2004; 104(11): 2914 - 2914. [Abstract]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020